OR WAIT null SECS
Through the agreement, Samsung will provide flexible business terms while offering full regulatory support and improved batch release from small to large scale.
Samsung Biologics announced it is entering into a long-term agreement with Ichnos Sciences, a Paramus, NJ-based biotech company, for the manufacturing of drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis.
Through the agreement, Samsung will provide flexible business terms while offering full regulatory support and improved batch release from small to large scale, according to Samsung.
“As we progress our pipeline of clinical-stage assets, including our most advanced biologic, ISB 830, we are pleased to continue to work with Samsung Biologics to ensure continued drug substance supply for ISB 830,” said Alessandro Riva, MD, CEO of Ichnos Sciences, in a Nov. 5, 2019 press release. “We look forward to a mutually beneficial collaboration as we continue developing ISB 830 for autoimmune diseases, including atopic dermatitis.”
"We are extremely proud to advance our ongoing relationship with Ichnos and truly appreciate the trust they have placed in Samsung Biologics to ensure delivery of high quality ISB 830 drug supply for clinical studies and for potential future commercial supply,” added Dr. Tae Han Kim, CEO of Samsung Biologics, in the press release. “Client satisfaction is our highest priority, and we look forward to generating future value for Ichnos via our continued collaboration.”
Testing on ISB 830 in a randomized placebo-controlled Phase IIb study in atopic dermatitis was recently completed, and the results will be available during early 2020.